Barclays Maintains Overweight on 10x Genomics, Raises Price Target to $110

Barclays analyst Luke Sergott has maintained an Overweight rating on 10x Genomics (NASDAQ: TXG) and raised the price target from $52 to $110. This adjustment reflects a positive outlook on the company's performance.